Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IIV-HD + NVXC19 Combination Vaccine in Adults 60+
NCT07890454Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Sanofi. Primary endpoints: Antibody titers against for each of the 3 influenza vaccine strains at Day 28 and Antibody titers against SARS-CoV-2 specific variant at Day 28. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT07890454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890454.